Key facts
- This page summarizes Chris Nolet's Form 4 filing for ArriVent BioPharma, Inc. (AVBP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 20 Jun 2025, 19:29.
Chris Nolet - 18 Jun 2025 Form 4 Insider Report for ArriVent BioPharma, Inc. (AVBP)
- Reporting relationship
- Director
- Issuer ticker
- AVBP
- Reported as of
- 18 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Jun 2025, 19:29:56 UTC
- Prior SEC filing
- 06 Feb 2025
- Next SEC filing
- 03 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ James Kastenmayer, Attorney-in-Fact for Chris Nolet
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chris Nolet filed Form 4 for ArriVent BioPharma, Inc. (AVBP) on 20 Jun 2025.
Change
- Previous filing in this sequence was filed on 06 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001782814
Primary reporting owner
Nolet Chris
- Relationship
- Director
- Address
- C/O ARRIVENT BIOPHARMA, INC., 18 CAMPUS BOULEVARD SUITE 100, NEWTOWN SQUARE
- Signature
- By: /s/ James Kastenmayer, Attorney-in-Fact for Chris Nolet
- Signature date
- 20 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVBP
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +15,502
- Change %
- Price
- $0.000000
- Shares after
- 15,502
- Date
- 18 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,502
- Exercise price
- $24.89
* marks a reported price that did not pass the local price check.